Xeris Biopharma Holdings (XERS) Other Gross PP&E Adjustments (2020 - 2025)
Xeris Biopharma Holdings (XERS) has disclosed Other Gross PP&E Adjustments for 6 consecutive years, with -$13.8 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Other Gross PP&E Adjustments rose 29.51% year-over-year to -$13.8 million, compared with a TTM value of -$13.8 million through Dec 2025, up 29.51%, and an annual FY2025 reading of -$13.8 million, up 29.51% over the prior year.
- Other Gross PP&E Adjustments was -$13.8 million for Q4 2025 at Xeris Biopharma Holdings, down from -$12.2 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $11.0 million in Q2 2022 and bottomed at -$19.5 million in Q4 2024.
- Average Other Gross PP&E Adjustments over 5 years is -$8.0 million, with a median of -$13.8 million recorded in 2025.
- The sharpest move saw Other Gross PP&E Adjustments tumbled 5426.05% in 2024, then increased 29.51% in 2025.
- Year by year, Other Gross PP&E Adjustments stood at $7.6 million in 2021, then crashed by 82.28% to $1.3 million in 2022, then crashed by 1509.9% to -$18.9 million in 2023, then dropped by 2.98% to -$19.5 million in 2024, then rose by 29.51% to -$13.8 million in 2025.
- Business Quant data shows Other Gross PP&E Adjustments for XERS at -$13.8 million in Q4 2025, -$12.2 million in Q3 2025, and -$15.0 million in Q2 2025.